Is CLRYF or JNJ a better dividend investment in 2026?

CLRYF currently yields 2000000.00% with a 5% 5-year dividend growth rate. JNJ yields 2.14% with 5.8% growth. The better choice depends on your goal: CLRYF offers higher current income.

What is the dividend yield difference between CLRYF and JNJ?

CLRYF has a forward dividend yield of 2000000.00% ($2.00/share annually). JNJ yields 2.14% ($5.20/share annually). The yield gap is 1999997.86 percentage points.

Home › Compare › CLRYF vs JNJ

CLRYF vs JNJ: Dividend Comparison 2026

CLRYF yields 2000000.00% · JNJ yields 2.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CLRYF wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CLRYF

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full CLRYF calculator →

JNJ

Johnson & Johnson

● Live price

2.14%

Share price

$242.49

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.5K

Annual income

$4,749.88

Full JNJ calculator →

Portfolio growth — CLRYF vs JNJ

📍 CLRYF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CLRYF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CLRYF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CLRYF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLRYF

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$182.28/yr

After 10yr DRIP, annual income (after tax)

$4,037.40/yr

At 15% tax rate, CLRYF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLRYF + JNJ for your $10,000?

CLRYF: 50%JNJ: 50%

100% JNJ50/50100% CLRYF

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CLRYF

No analyst data

Altman Z

-26.5

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-5.7% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLRYF buys

JNJ buys

No recent congressional trades found for CLRYF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCLRYFJNJ

Forward yield	2000000.00% ✓	2.14%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$4.879226400974806e+39M	$30.5K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$4,749.88
Total dividends collected	$4.879195005460081e+39M	$15.6K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: CLRYF vs JNJ ($10,000, DRIP)

Year	CLRYF Portfolio	CLRYF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$10,594	$274.49	+$200.00M → CLRYF
2	$3,738,731,768,458	$3,738,517,757,009.35	$11,294	$360.69	+$3738731.76M → CLRYF
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$12,133	$476.91	+$65315062866.92M → CLRYF
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$13,156	$635.42	+$1066400830062625.00M → CLRYF
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$14,432	$854.61	+$16272182796453826560.00M → CLRYF
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$16,056	$1,162.76	+$2.3205424011366188e+23M → CLRYF
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$18,175	$1,604.53	+$3.0927990661046884e+27M → CLRYF
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$21,009	$2,252.68	+$3.8524105697352695e+31M → CLRYF
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$24,911	$3,229.73	+$4.484688260147987e+35M → CLRYF
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$30,458	$4,749.88	+$4.879226400974806e+39M → CLRYF

CLRYF vs JNJ: Complete Analysis 2026

CLRYF — Stock

Clarocity Corporation designs and develops real estate valuation and report products. The company develops software for residential housing appraisal research in the metropolitan areas throughout the United States, as well as a suite of realtor powered valuation products. It also provides alternative valuation and appraisal fulfillment services. The company was formerly known as Zaio Corporation and changed its name to Clarocity Corporation in October 2016. Clarocity Corporation is headquartered in Carlsbad, California.

Full CLRYF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this CLRYF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLRYF vs SCHD CLRYF vs JEPI CLRYF vs O CLRYF vs KO CLRYF vs MAIN CLRYF vs ABBV CLRYF vs MRK CLRYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.